FOCUSED ON DEVELOPING AN INNOVATIVE TREATMENT FOR COGNITIVE IMPAIRMENT due to raised cortisol ASSOCIATED WITH NEUROLOGICAL, PSYCHIATRIC, AND METABOLIC DISEASES

Actinogen Medical Annual General Meeting
The 2020 Annual General Meeting was held at 10.30am AEDT on Friday, 27 November 2020 as a fully virtual online event.
View Webcast Presentation
Annual Report to Shareholders Year Ended 30 June 2020
Actinogen Medical released its Annual Report to Shareholders for year ended 30 June 2020
View Annual Report Year Ended 30 June 2020
Actinogen announces new clinical trials & launches capital raising
Actinogen is pleased to announce two new clinical trials and launches capital raising. Fragile X syndrome (FXS) selected as an additional indication for Xanamem, ACW’s lead compound. In addition, we plan to initiate a new phase II clinical trial in Mild Cognitive Impairment due to Alzheimer’s disease.
View ASX Announcement
Conference Call Webcast
Actinogen hosted a conference call on Monday, 19 October 2020 with an update on the clinical development plans for Xanamem. Dr. Bill Ketelbey, CEO and MD of Actinogen, provided an overview of the new indication in Fragile X syndrome, the planned Alzheimer’s disease and Fragile X syndrome phase II clinical trials, and the capital raising to support the Alzheimer’s trial.
Watch webcast
VIEW FULL PRESENTATION AT AAT-AD/PD
Actinogen is proud to have contributed its data generated on Xanamem, to this body of knowledge and to provide the full presentation as presented by Professor Craig Ritchie, Chair of Actinogen’s Xanamem Clinical Advisory Board.
View Presentation
Previous
Next

About Us

Actinogen Medical (ASX:ACW) is an ASX-listed, biotechnology company developing an innovative treatment for cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. ‘Cognition’ relates to how a person understands and acts in the world around them. Cognitive functions include memory, reasoning, awareness and decision-making, and to a large extent, influences our personality.

Actinogen Medical’s lead drug candidate, Xanamem, has been specifically designed to block the production of cortisol – the stress hormone – in the brain. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s disease, anxiety in Fragile X syndrome, and cognitive impairment in schizophrenia and diabetes. 

Xanamem offers a promising new approach to treat cognitive impairment associated with these neurodegenerative, psychiatric, and metabolic diseases.

In the Company’s recent XanaHES Phase I trial, Xanamem exhibited a statistically significant improvement in cognition among healthy elderly volunteers treated with 20mg Xanamem daily, building on the encouraging data from the earlier XanADu study. The Company plans to initiate a range of Phase II studies evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease, Fragile X syndrome, schizophrenia, and diabetes.

Subscribe to Our Newsletter

Actinogen 2020 ™
Contact Us